Evidence map›Paper›PMID 22716313›Full record

ArticleJournal of biological engineering2012

A BioBrick compatible strategy for genetic modification of plants.

Patrick M Boyle, Devin R Burrill, Mara C Inniss, Christina M Agapakis, Aaron Deardon, Jonathan G DeWerd, Michael A Gedeon, Jacqueline Y Quinn, Morgan L Paull, Anugraha M Raman and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of biological engineering, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Patrick M Boyle *Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Devin R Burrill *Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Mara C Inniss *Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Christina M Agapakis *Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Aaron DeardonHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Jonathan G DeWerdHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Michael A GedeonHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Jacqueline Y QuinnHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Morgan L PaullHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Anugraha M RamanHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Mark R TheilmannHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Lu WangHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Julia C WinnHarvard College, Harvard University, Cambridge, MA, 02138, USA.
Oliver MedvedikDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA.
Kurt SchellenbergThe Arnold Arboretum of Harvard University, Boston, MA, 02131, USA.
Karmella A HaynesDepartment of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Alain VielDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA.
Tamara J BrennerDepartment of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA.
George M ChurchWyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Jagesh V ShahDepartment of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.
Pamela A SilverDepartment of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelled

backgroundPlant biotechnology can be leveraged to produce food, fuel, medicine, and materials. Standardized methods advocated by the synthetic biology community can accelerate the plant design cycle, ultimately making plant engineering more widely accessible to bioengineers who can contribute diverse creative input to the design process.

resultsThis paper presents work done largely by undergraduate students participating in the 2010 International Genetically Engineered Machines (iGEM) competition. Described here is a framework for engineering the model plant Arabidopsis thaliana with standardized, BioBrick compatible vectors and parts available through the Registry of Standard Biological Parts (http://www.partsregistry.org). This system was used to engineer a proof-of-concept plant that exogenously expresses the taste-inverting protein miraculin.

conclusionsOur work is intended to encourage future iGEM teams and other synthetic biologists to use plants as a genetic chassis. Our workflow simplifies the use of standardized parts in plant systems, allowing the construction and expression of heterologous genes in plants within the timeframe allotted for typical iGEM projects.

Identifiers

PMID22716313
PMCPMC3537565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.